Pharmaceutical industry

Genpro Appoints Steve Herbert as the Chief Commercial Officer of Genpro Research Inc.

Cision, Pharmaceutical industry, Articles, Companies

Friday, September 18, 2020 - 6:00pm

BOSTON, Sept. 18, 2020 /PRNewswire-PRWeb/ --Genpro Research today announced the appointment of Steve Herbert as Chief Commercial Officer of Genpro Research Inc., leading the commercial, BD and sales strategy.

Key Points:

BOSTON, Sept. 18, 2020 /PRNewswire-PRWeb/ --Genpro Research today announced the appointment of Steve Herbert as Chief Commercial Officer of Genpro Research Inc., leading the commercial, BD and sales strategy.
Mr. Herbert brings over 20 years of commercial leadership and expertise in the US & European Clinical Research & Pharmaceutical software markets as well as an in-depth knowledge of the pharmaceutical industry.
"Steve's appointment demonstrates the continued commitment of Genpro Research to expanding the scope and reach of our products and services to our global customers," said Anoop Ambika, Chief Executive Officer of Genpro Research.
"Over the last 24 months, Genpro Research has been rapidly expanding and increasing its footprint in India and US.

UAE Pharmaceutical Life Science Market Drug Medicine Retail Pharmacy Sales Unit Price Cost Database Report 2020

Western Asia, Geography of Asia, Asia, Arab world, United Arab Emirates, Pharmaceutical industry

Friday, September 18, 2020 - 5:51pm

The pharmaceutical market in UAE is also powered by increasing research and development activities as well as the by incorporating more elements that have made the market a top destination for conducting clinical research studies.

Key Points:

The pharmaceutical market in UAE is also powered by increasing research and development activities as well as the by incorporating more elements that have made the market a top destination for conducting clinical research studies.
Gain of productivity and increase in the technological advancement in the market are estimated to significantly strengthen the position of UAE in the pharmaceutical market.
As per the analysis for UAE pharmaceutical market, the country is emerging as a large power in the overall GCC pharmaceutical industry.
The impressive figures achieved from the UAE pharmaceutical industry indicates several significant opportunities for the future growth as well as attractive trends for the future navigation of the market into highly recognizable market.

UAE Pharmaceutical Life Science Market Drug Medicine Retail Pharmacy Sales Unit Price Cost Database Report 2020

Western Asia, Geography of Asia, Asia, Arab world, United Arab Emirates, Pharmaceutical industry

Friday, September 18, 2020 - 5:46pm

The pharmaceutical market in UAE is also powered by increasing research and development activities as well as the by incorporating more elements that have made the market a top destination for conducting clinical research studies.

Key Points:

The pharmaceutical market in UAE is also powered by increasing research and development activities as well as the by incorporating more elements that have made the market a top destination for conducting clinical research studies.
Gain of productivity and increase in the technological advancement in the market are estimated to significantly strengthen the position of UAE in the pharmaceutical market.
As per the analysis for UAE pharmaceutical market, the country is emerging as a large power in the overall GCC pharmaceutical industry.
The impressive figures achieved from the UAE pharmaceutical industry indicates several significant opportunities for the future growth as well as attractive trends for the future navigation of the market into highly recognizable market.

Japan Cancer Oncology Drug Therapeutics Market Sales Size Offers US$ 15 Billion Opportunity With 1600 Drug In Clinical Trials

Health, Articles, Medicine, Pharmaceutical industry, Oncology, Drug discovery, Food and Drug Administration, Clinical research, Clinical trial, Chemotherapy, Cancer, Cancer survival rates

Friday, September 18, 2020 - 3:57pm

NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

Key Points:

NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:
Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
Insight on Cancer Drugs In Clinical Trials: 360 Drugs
Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
Marketed Cancer Drug Clinical Insight by Companies & Indication: 141 Drugs
Cancer Clinical Pipeline By Company, Indication & Phase
Japan in the past few years have been observing influx in the record of novel oncology drugs that have been approved and getting used to treat millions of patients that are suffering from any type of cancer.
As per the report findings for Japan Cancer Drug Market, spending of the revenue in Japan is mostly concentrated towards the cancer types that have been prevailing badly in the country.
All this is estimated to impact the cancer drug market and the costs of the drug in Japan over the next decade.
Overall, the cancer drug market in Japan is estimated to reach numerous billion dollars in the coming years, leveraging the country to be the most dominant cancer drug market in Asia.

Japan Cancer Oncology Drug Therapeutics Market Sales Size Offers US$ 15 Billion Opportunity With 1600 Drug In Clinical Trials

Health, Articles, Medicine, Pharmaceutical industry, Oncology, Drug discovery, Food and Drug Administration, Clinical research, Clinical trial, Chemotherapy, Cancer, Cancer survival rates

Friday, September 18, 2020 - 3:59pm

NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

Key Points:

NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:
Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
Insight on Cancer Drugs In Clinical Trials: 360 Drugs
Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
Marketed Cancer Drug Clinical Insight by Companies & Indication: 141 Drugs
Cancer Clinical Pipeline By Company, Indication & Phase
Japan in the past few years have been observing influx in the record of novel oncology drugs that have been approved and getting used to treat millions of patients that are suffering from any type of cancer.
As per the report findings for Japan Cancer Drug Market, spending of the revenue in Japan is mostly concentrated towards the cancer types that have been prevailing badly in the country.
All this is estimated to impact the cancer drug market and the costs of the drug in Japan over the next decade.
Overall, the cancer drug market in Japan is estimated to reach numerous billion dollars in the coming years, leveraging the country to be the most dominant cancer drug market in Asia.

Global Contract Research Organization (CRO) Markets, 2019-2020 & 2024: Increased Adoption of Hybrid Clinical Trials and Remote Patient Monitoring

Health, Clinical research, Articles, Pharmaceutical industry, Medical research, Contract research organization, Clinical trial, Functional sourcing

Friday, September 18, 2020 - 2:30pm

DUBLIN, Sept. 18, 2020 /PRNewswire/ -- The "Post-Pandemic Growth Opportunity in the Global Contract Research Organization (CRO) Market" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Sept. 18, 2020 /PRNewswire/ -- The "Post-Pandemic Growth Opportunity in the Global Contract Research Organization (CRO) Market" report has been added to ResearchAndMarkets.com's offering.
With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new trials.
It presents an overview and analysis of the global clinical trials and research outsourcing (CRO) market.
The two key market trends identified are the increased adoption of hybrid clinical trials and remote patient monitoring.

Global Big Pharma Partnering Deal Terms and Agreements Directory 2020: Access Agreements Announced in the Life Sciences Since 2014 - ResearchAndMarkets.com

Health, Pharmaceutical, Pharmaceutical industry, Big Pharma

Friday, September 18, 2020 - 2:53pm

Global Big Pharma Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals.

Key Points:

Global Big Pharma Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals.
This report provides details of the latest Big Pharma agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.
Insight into terms included in a Big Pharma partnering agreement, with real world examples
Available deals are listed by:

Global Pharmaceutical Partnering Deal Terms and Agreements Analysis Report 2016-2020 - ResearchAndMarkets.com

Health, Pharmaceutical, Articles, Pharmaceutical industry, Pharmacology, Pharmacy, Life sciences, Pharmaceuticals policy

Friday, September 18, 2020 - 2:34pm

The "Global Pharmaceutical Partnering Terms and Agreements 2016-2020" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Global Pharmaceutical Partnering Terms and Agreements 2016-2020" report has been added to ResearchAndMarkets.com's offering.
Global Pharmaceutical Partnering Terms and Agreements 2016 to 2020 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals.
The report takes the reader through a comprehensive review Pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Pharmaceutical partnering deals.
Insight into terms included in a Pharmaceutical partnering agreement, with real world examples
Available deals are listed by:

PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trials

Health, Pharmaceutical industry, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments

Friday, September 18, 2020 - 1:30pm

RALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) and Deep Lens, Inc., announced today a new strategic relationship to accelerate patient access and recruitment for oncology clinical trials.

Key Points:

RALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) and Deep Lens, Inc., announced today a new strategic relationship to accelerate patient access and recruitment for oncology clinical trials.
Using Deep Lens VIPER technology, the patient identification process will be streamlined by instantly analyzing data within electronic health records, pathology systems and genomic profiles to enable matching of cancer patients with suitable clinical trials.
Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.
Growing with sponsors, providers, and strategic partners, Deep Lens challenges the status quo so that patients can get the therapies they want and deserve.

Worldwide Risk-based Monitoring Software Industry to 2026 - Featuring MasterControl, Veeva Systems & Techso Among Others - ResearchAndMarkets.com

Technology, Software, Health, Pharmaceutical industry, Clinical research, Articles, Clinical pharmacology, Clinical trial, Design of experiments

Friday, September 18, 2020 - 1:05pm

The "Global Risk-based Monitoring Software Market Analysis 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Global Risk-based Monitoring Software Market Analysis 2020" report has been added to ResearchAndMarkets.com's offering.
The Global Risk-based Monitoring Software market is expected to reach $652.40 million by 2026 growing at a CAGR of 15.3% from 2019 to 2026.
Risk-based monitoring (RBM) software is a clinical trial-monitoring method that fulfills regulatory necessities.
It employs various tools, platforms and dashboards to identify signals, which indicate potential issues with trial conduct, safety, data integrity, compliance and enrollment.